Hepatitis C: Alisporivir (ALV) 600 mg twice daily (BID) with Peginterferon alfa-2a (PEG) and ribavirin (RBV) for 1 week, followed by an additional 23 or 47 weeks according to response-guided treatment duration (RGT)

The 50% effective concentration for inhibition of HCV subgenomic replicon replication in Huh 5-2 cells (luciferase assay) by DEBIO-025 was 0.27 +/- 0.03 ug/mL and for CsA 2.8 +/- 0.4 ug/mL. The concentration that reduced the growth of exponentially proliferating Huh 5-2 cells by 50% was greater than 27 ug/mL for DEBIO-025 and 12 +/- 6 ug/mL for CsA, resulting in a selectivity index of approximately 900 for DEBIO-025 and 40 for CsA. DEBIO-025, at concentrations of 0.5 and 1 ug/mL, was able to clear cells from their HCV replicon within three to four passages, whereas treatment with CsA at the same concentrations for seven consecutive passages did not result in clearance of the HCV replicon.